{
    "nctId": "NCT01192308",
    "briefTitle": "PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)",
    "officialTitle": "PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 42,
    "primaryOutcomeMeasure": "Tamoxifen and metabolites plasmaconcentration",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Subject is at least 18 years at screening.\n* Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.\n* Subject is a female patient with (a history of) breast cancer and has been treated with tamoxifen 20mg QD for at least 4 weeks and is expected to be treated for at least another 4 weeks\n\nExclusion Criteria:\n\n* Inability to understand the nature and extent of the trial and the procedures required.\n* Participation in a drug trial within 60 days prior to the first dose.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}